TGF-β inhibits T cell-mediated tumor clearance in vivo by specifically inhibiting the expression of five cytolytic gene products, including perforin, granzyme A, granzyme B, Fas ligand, and IFN-γ, in CTLs30. This evidence concerns the gene PRF1 and neoplasm.